Oxurion to Participate in Needham Virtual Healthcare Conference

Leuven, BELGIUM, Boston, MA, US - MARCH 28, 2022 – 8.00 AM CET  – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announces today that Tom Graney, Chief Executive Officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 9:30 AM ET.

A live webcast and 90-day archive will be available in the “Investors” section of the Company’s website. 

 About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For more information, please contact:

Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10[email protected]     Michaël DillenChief Business OfficerTel: +32 479 783 583[email protected]

EUMEDiSTRAVA ConsultingDavid Dible/ Sylvie Berrebi/Frazer HallTel: +44 203 928 6900[email protected]   USWestwicke, an ICR CompanyChristopher BrinzeyTel: +1 617 835 9304[email protected]

Source: Oxurion NV

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Striding AI Announces Development of Next-Generation Robotic Foundation Systems for Physical AI Deployment
• NOFLTRS Expands Its Statement Apparel Collection, Reinforcing a New Category of Wearable Self-Expression
• 4DMedical Receives TGA Approval for CT:VQ™, Bringing Non-Contrast Ventilation-Perfusion Imaging to Australia